{"DataElement":{"publicId":"7801140","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Total Dose Administered Value","preferredDefinition":"A description of the total dose of filgrastim or bioequivalence agent that was administered.","longName":"7801133v1.0:7801117v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7801133","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Total Dose Administered","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. _An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. _An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._In medicine, the total amount of a drug or radiation given to a patient over time; for example, the total dose of radiation given in a series of radiation treatments._The act of having given something (medication or test).","longName":"7810079v1.0:5775595v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7810079","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C1474:C37998:C71763:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0117CDB-A5DF-5E9A-E053-4EBD850ABA81","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5775595","version":"1","preferredName":"Cumulative Dose Administered","preferredDefinition":"In medicine, the total amount of a drug or radiation given to a patient over time; for example, the total dose of radiation given in a series of radiation treatments.:The act of having given something (e.g., a medication or test).","longName":"C94394:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cumulative Dose","conceptCode":"C94394","definition":"The total amount of an agent (e.g., drug, biologic, radiation, etc.) administered to a subject over a defined period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D117A40-C96D-494B-E053-F662850A04E3","latestVersionIndicator":"Yes","beginDate":"2017-04-13","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-13","modifiedBy":"ONEDATA","dateModified":"2017-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B6FDD-6835-0D4E-E053-4EBD850A8723","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-28","modifiedBy":"MALUMK","dateModified":"2021-12-20","changeDescription":"Released. 12/20/2021 KMM; System gen def too long so saved as ALT def. 11/05/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7801117","version":"1","preferredName":"Filgrastim Or Bioequivalence Total Dose Value","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1)._The total amount of an agent (e.g., drug, biologic, radiation, etc.) administered to a subject over a defined period of time._A numerical quantity measured or assigned or computed.","longName":"7801117v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1080 ug","valueDescription":"1080 Microgram","ValueMeaning":{"publicId":"7801118","version":"1","preferredName":"1080 Microgram","longName":"7801118","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::1080: A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Microgram","conceptCode":"C48152","definition":"A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5E3003-54B2-0ECE-E053-4EBD850A59E1","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF692032-D8CD-49FD-E053-4EBD850AAD90","beginDate":"2021-10-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"600 ug","valueDescription":"600 Microgram","ValueMeaning":{"publicId":"7801121","version":"1","preferredName":"600 Microgram","longName":"7801121","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::600: A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Microgram","conceptCode":"C48152","definition":"A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5E3003-5538-0ECE-E053-4EBD850A59E1","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF692032-D8E1-49FD-E053-4EBD850AAD90","beginDate":"2021-10-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"900 ug","valueDescription":"900 Microgram","ValueMeaning":{"publicId":"7801119","version":"1","preferredName":"900 Microgram","longName":"7801119","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::900: A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Microgram","conceptCode":"C48152","definition":"A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5E3003-54EC-0ECE-E053-4EBD850A59E1","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF692032-D8F5-49FD-E053-4EBD850AAD90","beginDate":"2021-10-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"780 ug","valueDescription":"780 Microgram","ValueMeaning":{"publicId":"7801120","version":"1","preferredName":"780 Microgram","longName":"7801120","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::780: A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Microgram","conceptCode":"C48152","definition":"A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5E3003-5512-0ECE-E053-4EBD850A59E1","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF692032-D936-49FD-E053-4EBD850AAD90","beginDate":"2021-10-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"960 ug","valueDescription":"960 Microgram","ValueMeaning":{"publicId":"7801124","version":"1","preferredName":"960 Microgram","longName":"7801124","preferredDefinition":"A number with no fractional part, including the negative and positive numbers as well as zero.::960: A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Microgram","conceptCode":"C48152","definition":"A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF692032-D943-49FD-E053-4EBD850AAD90","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF692032-D95C-49FD-E053-4EBD850AAD90","beginDate":"2021-10-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7810088","version":"1","preferredName":"Filgrastim Or Bioequivalence Cumulative Dose Value","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).:In medicine, the total amount of a drug or radiation given to a patient over time; for example, the total dose of radiation given in a series of radiation treatments.:A numerical quantity measured or assigned or computed.","longName":"7810088v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cumulative Dose","conceptCode":"C94394","definition":"The total amount of an agent (e.g., drug, biologic, radiation, etc.) administered to a subject over a defined period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00E0003-00E6-6E8C-E053-4EBD850AC4A8","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5E3003-548F-0ECE-E053-4EBD850A59E1","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-27","modifiedBy":"MALUMK","dateModified":"2021-12-20","changeDescription":"Released. 12/20/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the total dose of fi","type":"Preferred Question Text","description":"What was the total dose of filgrastim that was administered?","url":null,"context":"NHLBI"},{"name":"Total dose of drug administered","type":"Application Standard Question Text","description":"Total dose of drug administered","url":null,"context":"NHLBI"},{"name":"Total dose of drug administered","type":"Alternate Question Text","description":"Total dose of drug administered","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B883E-BABF-21FE-E053-4EBD850A2AF8","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-10-28","modifiedBy":"MALUMK","dateModified":"2021-12-20","changeDescription":"Released. 12/20/2021 KMM; Released. 12/20/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}